Live Breaking News & Updates on Molecular Residual Disease|Page 2

Share this article
Share this article
SAN FRANCISCO, May 4, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021.
We had a very strong start to the year, experiencing record daily volumes, and we expect that momentum to continue into the coming years, said Sean George, co-founder and chief executive officer of Invitae. Genetic information is the foundation for personalized medicine, and we believe Invitae is uniquely positioned to deliver that information from a single platform across all stages of life, ushering personalized medicine into the mainstream to improve healthcare for all. ....

United States , North Carolina , Research Triangle Park , Laura Dangelo , Sean George , Prnewswire Invitae Corporation , Softbank Group Corp , Janssen Research Development , Development Expense , Invitae Corporation , Roche Group , National Human Genome Research Institute , Bristol Myers Squibb , American College Of Medical Genetics , One Codex , Medical Genetics , Annual Clinical Genetics Meeting , Janssen Research , Molecular Residual Disease , Acute Myeloid Leukemia , Conference Call , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Months Ended March , Operating Expense ,